SAB Biotherapeutics shares rise 13.17% intraday after positive Phase 1 trial results and $175M funding.

think> Okay, let's see. The user wants me to transform the given text into a concise news headline following specific rules. The example provided is in Chinese, but the output needs to be in English. The input here is about SAB Biotherapeutics, and the key points are the stock price increase during intraday trading, the Phase 1 data, the financial raise, and the advancement to Phase 2b. First, I need to extract the company name: SAB Biotherapeutics. The percentage is 13.17073171%, which should be rounded to two decimal places, so 13.17%. The time period is intraday. The reason for the price movement has multiple points. The example includes two main reasons in the first paragraph. Here, there are three points: Phase 1 data, financial raise, and Phase 2b. I need to pick the most significant ones. The Phase 1 data showing no decline in C-peptide levels is a key scientific result. The financial raise of $175 million is also important for funding. The Phase 2b trial advancement is another major milestone. However, the example only includes two reasons. Maybe the user expects to include the top two reasons. The example's structure has the headline with the company name, percentage, time, and a brief reason. Then the next paragraph provides more details. So, I should follow that. The first sentence should mention the surge, the time, and the main reasons. Then, the second paragraph can elaborate on the details. Wait, the user's example has the company's focus in the second paragraph. But in the input here, the company's focus isn't mentioned. The example's second paragraph explains the company's focus. However, in the current input, the company's description isn't provided, so maybe I don't need to include that. The user's rules don't mention including the company's focus, just the reason for the price movement. So, the headline should include the company name, percentage, time, and a brief reason. The brief reason here could be the Phase 1 data and the financial raise. The third point about the Phase 2b trial is another reason but maybe not necessary if we need to keep it concise. Let me check the example again. The example includes two reasons in the first paragraph. Here, there are three, but perhaps the main ones are the Phase 1 data and the financial raise. The Phase 2b is an additional point. Wait, the user's rules say "provide a brief reason for the price movement, retaining key information." So, need to include key points. The Phase 1 data is a key scientific result, the financial raise is important for funding, and the Phase 2b is another key development. But maybe the user wants to mention all three? However, the example only includes two. Let me check the example's input. The example's input had two reasons: the project agreement and the company's focus. So, in this case, maybe the three reasons are too much. The user might expect to pick the top two. Alternatively, the example's output includes the main reason in the first sentence and the company's focus in the second. Here, perhaps the first sentence includes the two main reasons (Phase 1 data and the financial raise), and the Phase 2b can be part of the next paragraph. So, the headline would be: "SAB Biotherapeutics surged 13.17% intraday, citing positive Phase 1 data for SAB-142 in type 1 diabetes and a $175 million funding raise. The company is advancing SAB-142 into a pivotal Phase 2b trial, with enrollment expected to complete by year-end 2026." Wait, the user's example uses "with the company announcing..." structure. Let me structure it similarly. First sentence: "SAB Biotherapeutics surged 13.17% intraday, citing positive Phase 1 data for SAB-142 in type 1 diabetes and a $175 million funding raise." Second paragraph: "The company announced additional Phase 1 data showing no decline in C-peptide levels in participants at 120 days, indicating early preservation signals. On March 9, 2026, SAB Biotherapeutics reported 2025 financial results, securing $1.75 billion through an oversubscribed private placement, ensuring sufficient capital through 2028. The company has advanced SAB-142 into the registration-enabling Phase 2b SAFEGUARD study, enrolling multiple patients and expecting to complete enrollment by the end of 2026." Wait, but the funding raised is $1.75 billion? The input says "筹集$1.75亿", which is $17.